| 1 |
Guideline [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers] 2007
Bourguet P, Planchamp F, Montravers F, Vincendeau S, Anonymous00058, Anonymous00059. · Comité rédacteur SOR, INCA, FNCLCC, La Ligue, FHF FNCHRU, FFC et AFU, Centre Eugène Marquis, Rennes, France. · Prog Urol. · Pubmed #17489312 No free full text.
This publication has no abstract.
|
| 2 |
Guideline [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder] free! 2006
Bourguet P, Planchamp F, Montravers F, Vincendeau S, Courbon F, Edeline V, Helal BO, Rossi D, Villers A, Anonymous00504, Anonymous00505, Anonymous00506, Anonymous00507, Anonymous00508, Anonymous00509, Anonymous00510, Anonymous00511. · Centre Eugène-Marquis, Rennes. · Bull Cancer. · Pubmed #17191352 links to free full text
This publication has no abstract.
|
| 3 |
Review [Clinical usefulness of positron emission tomography in prostate cancer] 2007
Talbot JN, Gutman F, Huchet V, Kerrou K, Balogova S, Kerrouche N, Montravers F, Grahek D, Cussenot O, Gattegno B, Thibault P. · Service de médecine nucléaire, Hôpital Tenon, Université Pierre et Marie Curie, Paris. · Presse Med. · Pubmed #17524607 No free full text.
Abstract: In prostate cancer, use of FDG, the radiopharmaceutical currently most widely used in oncology, is limited to the most aggressive cancers and, in the absence of another tracer, to attempting to localise occult recurrences detected biochemically (elevated PSA serum levels). Four other PET tracers are currently suggested in various situations of prostate cancer development: for guiding biopsies, for diagnosis and staging of the primary cancer and of local or metastatic recurrences, especially in bone, and for localizing occult biochemical recurrence. This article is illustrated by cases summarising our experience with fluoromethylcholine-(18F) and PET/CT. They cover a wide spectrum of clinical settings: localisation of intraprostatic neoplastic lesions, initial staging, monitoring treatment by ultrasound, detection of occult recurrences and characterisation of images on conventional imaging modalities, which are questionable or difficult to interpret.
|
| 4 |
Article 18F-choline PET/CT for initial staging of advanced prostate cancer. free! 2006
Gutman F, Aflalo-Hazan V, Kerrou K, Montravers F, Grahek D, Talbot JN. · Service de Médecine Nucléaire, Hôpital Tenon, 4 rue de la Chine, Paris, France 75020. · AJR Am J Roentgenol. · Pubmed #17114515 links to free full text
This publication has no abstract.
|
|
|